

## Correction: Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers

Wu H, Chen Y, Wang Z, *et al.* Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers. *J Immunother Cancer* 2019;7:264. doi: 10.1186/s40425-019-0737-3


In the article titled ‘Alteration in TET1 as potential biomarker for immune checkpoint blockade in multiple cancers’, there is the following errors:

In the abstract, the sentence ‘Among twenty-one key genes involving in the regulation of DNA methylation, TET1-mutant (TET1-MUT) was enriched in patients responding to ICI treatment in the discovery cohort ( $p < 0.001$ )’ should instead read ‘Among twenty-one key genes involving in the regulation of DNA methylation, TET1-mutant (TET1-MUT) was enriched in patients responding to ICI treatment in the discovery cohort ( $p = 0.003$ )’

Additionally, in Figure 6:

1. Line 5, ‘HLA-DQA1’ should be ‘HLA-DQA2’
2. Line 51–69 (from ENDRB to TIGIT), the category of these genes ‘Other’ should be ‘Receptor’
3. Line 70–75 (from ARG1 to PRF1), the category of these genes ‘Receptor’ should be ‘Other’.

The correct Figure 6 can be seen below:



**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>.

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

*J Immunother Cancer* 2020;**8**:e0737-3corr1. doi:10.1136/jitc-2020-0737-3corr1

